Hospital General De Granollers

The Dermatology department at Hospital General De Granollers is integrating cutting‑edge diagnostic imaging and therapeutic devices to refine disease evaluation and personalize treatment strategies.

• Assessment of high‑resolution skin microscopy for early lesion detection
• Use of portable spirometry to monitor respiratory symptoms in allergic patients
• Implementation of digital adherence tools for chronic skin conditions

These technology‑focused efforts aim to enhance accuracy and efficiency across the site’s diverse clinical programs.

Researchers are investigating surgical adjuncts to improve outcomes after major abdominal procedures, including a study on a fibrin‑based adhesive designed to reduce anastomotic leaks following total gastrectomy for cancer.

• Evaluation of adhesive safety and effectiveness in postoperative healing
• Comparison with standard closure techniques
• Impact on hospital stay duration and complication rates

The goal is to provide surgeons with evidence‑based options that enhance patient recovery and lower morbidity.

A series of trials target allergic conditions triggered by house dust mites, testing a subcutaneous immunotherapy formulation to alleviate persistent rhinitis and conjunctivitis symptoms.

• Long‑term symptom relief assessment
• Quality‑of‑life measurements in adults
• Safety monitoring of repeated allergen exposure

By modulating the immune response, the research seeks to reduce reliance on daily antihistamines and improve daily functioning.

Although the primary focus is dermatology, the site collaborates on ocular studies that explore the link between skin inflammation and eye disease manifestations, especially in patients with atopic dermatitis.

• Correlation of skin severity scores with ocular surface inflammation
• Evaluation of topical therapies for concurrent eye irritation
• Patient‑reported outcomes on visual comfort

These investigations aim to provide integrated care pathways for individuals experiencing both cutaneous and ocular symptoms.

Multiple trials address disorders driven by immune dysregulation, including studies of novel biologics for atopic dermatitis and hidradenitis suppurativa, seeking to reduce inflammation and lesion formation.

• Comparison of new interleukin inhibitors with standard topical regimens
• Assessment of disease severity scales over 24‑week treatment periods
• Safety profiling in adolescent and adult populations

The overarching aim is to expand therapeutic options for patients whose conditions are inadequately controlled by existing treatments.

Oncology‑focused research at the Granollers hospital evaluates innovative approaches for non‑muscle invasive bladder cancer and early‑stage breast cancer, testing combinations of immunotherapy and targeted agents to improve disease‑free survival.

• Combination of BCG with a checkpoint inhibitor in bladder cancer
• Adjuvant use of a CDK4/6 inhibitor alongside endocrine therapy in hormone‑receptor positive breast cancer
• Long‑term follow‑up for recurrence monitoring

These studies seek to establish more effective, less invasive treatment regimens that maintain quality of life while reducing relapse risk.

The site conducts several investigations into chronic lung conditions, including trials of inhaled bronchodilators for asthma, novel agents for chronic obstructive pulmonary disease, and antifibrotic therapy for idiopathic pulmonary fibrosis.

• Non‑inferiority comparison of salbutamol monotherapy versus combination therapy in pediatric asthma exacerbations
• Effect of a new oral medication on COPD exacerbation frequency
• Safety and efficacy of a kinase inhibitor in slowing IPF progression

The purpose of these trials is to enhance symptom control, reduce hospital admissions, and slow disease progression for affected patients.

A robust portfolio of dermatologic studies targets conditions such as atopic dermatitis, hidradenitis suppurativa, and nummular eczema, evaluating both systemic biologics and topical formulations to achieve clearer skin and fewer lesions.

• Phase‑III assessment of lebrikizumab in moderate‑to‑severe atopic dermatitis
• Evaluation of sonelokimab versus placebo in hidradenitis suppurativa
• Investigation of a new topical cream for nummular eczema severity reduction

These efforts are designed to broaden therapeutic choices and improve long‑term disease management for patients with persistent skin disorders.

Beyond the primary therapeutic categories, Hospital General De Granollers supports exploratory studies that address mixed or rare conditions, ensuring inclusive research opportunities for all patient groups.

• Safety monitoring of long‑term biologic use across multiple skin diseases
• Cross‑disciplinary evaluation of allergic rhinitis patients with concurrent asthma
• Pilot study of personalized dosing algorithms for emerging dermatologic agents

These projects underscore the institution’s commitment to comprehensive, patient‑centered research that adapts to emerging clinical needs.